Humasis Co

Humasis Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Humasis Co (205470.KQ) as of Oct 27, 2026 is 4.37 %. In the previous year, CapEx to Operating Cash Flow Ratio was 4.55 % — a change of -4.03% (lower).

CapEx/OCF

4.37 %

YoY

-4.03%

Last updated:

CapEx to Operating Cash Flow Ratio of Humasis Co is 2025 4.37 % . CapEx to Operating Cash Flow Ratio of Humasis Co was 2024 4.55 % . It decreases by -4.03% lower compared to the previous year.

The Humasis Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-132.55 KRW
Jan 1, 2019
383.17 KRW
Jan 1, 2020
105.48 KRW
Jan 1, 2021
8.84 KRW
Jan 1, 2022
22.03 KRW
Jan 1, 2023
-42.02 KRW
Jan 1, 2024
4.55 KRW
Jan 1, 2025
4.37 KRW
The Humasis Co CapEx/OCF history
YEARCapEx/OCFYoY
4.37 %-4.03%
4.55 %-110.83%
-42.02 %-290.73%
22.03 %+149.35%
8.84 %-91.62%
105.48 %-72.47%
383.17 %-389.07%
-132.55 %+216.03%
-41.94 %—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

CapEx to Operating Cash Flow Ratio of Humasis Co is 4.37 % in 2025.

CapEx to Operating Cash Flow Ratio of Humasis Co changed from 4.55 % to 4.37 %, representing a -4.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Humasis Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humasis Co

All Key Metrics — Humasis Co